[The successful development of bisphosphonates in the therapy of osteoporosis].
In the last 30 years bisphosphonates have been used in the treatment of different bone diseases. Bisphosphonates in their oral pharmaceutical form are an established and approved medication in osteoporosis treatment for years. Latest research developed more potent bisphosphonates in different application forms: oral and parenteral. Therefore, their prospects for medical treatment could be enlarged to the fields of oncology, hematology, and osteology. Bisphosphonates are innovative in case of adjuvant therapy as well as in adequate pain therapy. In the medical treatment of osteoporosis and metabolic osteopathies bisphosphonates could be rightly denoted as groundbreaking.
Fassbender
Walter Josef
WJ
Hospital zum Hl. Geist Kempen, Akademisches Lehrkrankenhaus der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany. w.j.fassbender@krankenhaus-kempen.de
Stumpf
Ulla Cordula
UC
Kurth
Andreas
A
D000284:Administration, Oral; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy; D001862:Bone Resorption / Q000517:prevention & control; D004164:Diphosphonates / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004965:Estrogen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000517:prevention & control; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000517:prevention & control; D011322:Primary Prevention; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use; D040242:Risk Reduction Behavior
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D004965:Estrogen Antagonists; D020849:Raloxifene Hydrochloride